Search - tctmd.com

Displaying 1 - 20 of 107

Sort: Relevancy | Date

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

News Conference News TCT 2025

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

October 28, 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

April 03, 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

News Conference News THT 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

February 19, 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

February 12, 2025

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

News Conference News EuroPCR 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Yael L. Maxwell

May 17, 2024

EHRA, Others Update Consensus on Catheter and Surgical Ablation of AF

News Conference News EHRA 2024

EHRA, Others Update Consensus on Catheter and Surgical Ablation of AF

April 08, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Open SESAME? Transcatheter Myotomy Shows Promise for LVOT Obstruction

News Conference News CRT 2024

Open SESAME? Transcatheter Myotomy Shows Promise for LVOT Obstruction

March 12, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

AI-Based System Boosts Quality of Stroke Care and Reduces Events

News Conference News ISC 2024

AI-Based System Boosts Quality of Stroke Care and Reduces Events

February 16, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

Where You Live Matters More Than Hospital Volume for Heart Transplant Outcomes

News Conference News STS 2024

Where You Live Matters More Than Hospital Volume for Heart Transplant Outcomes

Yael L. Maxwell

February 06, 2024

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

News Conference News AHA 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Yael L. Maxwell

November 14, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.